1. INTRODUCTION
===============

Behavior is determined by interactions between genetic and environmental factors. Specific behavioral patterns are often associated with neurobehavioral disorders with a strong genetic background (*i.e.* autism and schizophrenia). Actually, there are a growing number of studies associating genetic abnormalities with specific behavioral phenotypes \[[@r1], [@r2]\]. The term "behavioral phenotype" has been recently introduced to describe a behavior featuring a biological condition associated with a certain genetic abnormality or syndrome \[[@r3]\]. Although many genetic conditions are not associated with highly specific behavioral phenotypes, there is a large number of syndromes originating from a genomic change and demonstrating characteristic behavioral features \[[@r4]-[@r8]\]. Nevertheless, underlying biological causes of specific behavioral manifestations resulting from genetic changes are extremely complicated and remain to be understood \[[@r9]\]. Still, genomic variations are consistently associated with specific behavioral phenotypes \[[@r10]-[@r14]\].

*De novo* and inherited genetic mutations leading to genomic variations are currently considered as a major biological cause of interindividual behavioral variability, especially in brain disorders (*i.e.* autism, schizophrenia, intellectual disability) \[[@r5], [@r8], [@r9], [@r11], [@r15]\]. Although it is commonly accepted that genomic variations generally affect all the cells of an organism due to meiotic errors \[[@r16]-[@r18]\], there are numerous studies evidencing that somatic or postzygotic genomic variations do accumulate during the early brain development and probably brain aging, originating from the failures of DNA replication/repair and cell cycle errors \[[@r19]-[@r21]\]. These types of genomic changes are defined as somatic genome variations or somatic mosaicism. Somatic mosaicism has been shown to be one of the promising yet underestimated mechanisms of phenotypic variability \[[@r22]-[@r26]\]. For instance, somatic mosaicism in the human brain has been proposed as a common mechanism for neurodevelopmental, neurobehavioral and neurodegenerative disorders \[[@r7], [@r27], [@r28]\]. Despite somatic mosaicism being detectable in almost all individuals \[[@r27]-[@r31]\], intercellular genomic diversification (genomic and chromosomal instability) has been found to be a highly probable mechanism for brain disorders including neurodegenerative and neurobehavioral diseases (*i.e.* Alzheimer's disease, autism and schizophrenia) and may produce dramatic changes in brain cellular physiology and behavior \[[@r32]-[@r47]\]. Mosaic genome variations accumulating or decreasing during lifetime may influence epigenetic and transcriptome patterns, ending up in functional and cellular diversity in the brain. The latter could negatively affect cell signaling pathways and neural circuit function leading to behavioral abnormalities and disease \[[@r7], [@r27], [@r28], [@r36], [@r40]-[@r43]\]. As a result, somatic mosaicism is now being addressed with respect to behavioral disorders \[[@r7], [@r19], [@r24], [@r27], [@r34], [@r42], [@r43]\]. The human brain responsible for speech, movement, cognition and other mental abilities is considered a primary target for studying the effect of somatic mosaicism on behavior and neuropsychiatric diseases. Single-cell analyses of brain cells in the healthy and diseased human brain have demonstrated that somatic mosaicism affects neuronal cell populations and is likely to mediate pathogenic processes associated with brain malfunctioning. Genomic changes are likely to be derived from disturbances in genome maintenance and cell cycle regulation pathways along with environmental influences (genetic-environmental interactions) \[[@r7], [@r27], [@r28], [@r32]-[@r47]\]. Accordingly, one can speculate that somatic genomic variations could also affect behavioral phenotypes.

Somatic mosaicism has been found in many genetic syndromes associated with behavioral abnormalities \[[@r1], [@r7], [@r48]-[@r51]\]. For instance, phenotypic features in patients with mosaic trisomy of chromosome 21 (Down syndrome) are determined by the percentage of trisomic cells present in different tissues \[[@r48], [@r49]\] (Fig. **[1](#F1){ref-type="fig"}**). Furthermore, somatic genome variations are generally dynamic. In other words, the amount of cells exhibiting altered genomes varies throughout lifespan \[[@r38], [@r51]-[@r55]\]. Therefore, one can speculate that variation of mosaicism levels is able to result in appreciable phenotypic changes including behavioral phenotypes. Interestingly, this assumption resembles to some extent the concept of the "dynamic genome", which is used for explaining genetic-environmental interactions modulating human behavior as well as consequences of stress and genomic adaptation to environmental effects \[[@r56]-[@r60]\]. However, similar theories leave aside somatic mosaicism without considering it as a mechanism for behavior variability.

Summarizing data on somatic mosaicism and its possible relevance for neurobiology and behavioral sciences, we have proposed a hypothesis suggesting that the levels of somatic mosaicism are constantly changing throughout ontogeny due to environmental effects affecting behavioral patterns. In its simplest form, the hypothesis can be postulated as follows: the amount of abnormal cells in an organism correlates with the behavioral patterns, *i.e.* the increase in the abnormal cell proportion is likely to have a negative behavioral effect, whereas a decrease is likely to have a positive one.

Since genomic variations affecting behavior are likely to be those confined to brain tissue \[[@r7]\], one should address somatic mosaicism/mutations in the brain *per se*. Regardless of overwhelming majority of human brain cells to be postmitotic, non-malignant brain cells are still prone to mutational events and DNA damage, which seem to accumulate during ontogeny in the aging human \[[@r61]-[@r63]\]. Notwithstanding, somatic genomic variations essentially are accumulated during the prenatal and early postnatal brain development \[[@r37], [@r55], [@r64]-[@r67]\]. Therefore, there is a need to modify the hypothesis.

Human brain is a highly plastic structure being especially predetermined to change in early childhood and is composed of a myriad of different neuronal cell types \[[@r64]\]. High levels of mosaic aneuploidy (loss/gain of chromosomes in a cell) hallmark the human developing brain being probably eliminated at later stages of life \[[@r51], [@r53], [@r55], [@r65]-[@r67]\]. However, genetically abnormal cells do remain in the postnatal brain.

CONCLUSION
==========

Consequently, an increase in the levels of abnormal cells might influence brain function, plasticity and performance \[[@r7], [@r27], [@r32]-[@r47]\]. In the behavioral context, neurodevelopmental diseases may be associated with a tissue-specific somatic mosaicism causing specific alterations to neural plasticity and interaction. We suggest that the higher is the percentage of mosaic cells among brain cells, the more severe are behavioral abnormalities. Additionally, somatic mosaicism in non-neuronal tissues has the potential to influence indirectly behavioral phenotype, as well. Since environmental factors are affecting levels of somatic mutations in mitotic tissues \[[@r23]-[@r26]\], these assumptions have relevance to therapeutic interventions \[[@r28]\]. Once the hypothesis is supported, new therapeutic opportunities for devastating neurobehavioral diseases would be available. Firstly, to do so, one needs to observe the effects described above in larger cohorts as well as studying somatic mosaicism in brain tissues. To correlate higher levels of somatic mosaicism with more severe behavioral manifestations, it is mandatory to perform a longitudinal study *via* genetic methodology and behavioral (psychologic) reports on an individual condition for a rather long period of time. One should keep in mind that it is impossible to obtain brain samples from a living individual to monitor somatic genome variations for a long period. However, it is possible to correlate the results of behavioral studies with somatic mosaicism evaluations in mitotic tissues and assessment of brain tissue susceptibility to genome instability uncovered by whole-genome scanning technologies (as suggested in \[[@r28], [@r68]\]). In addition, basic research of correlation between somatic mosaicism levels in mitotic and post-mitotic neuronal and non-neuronal (brain) tissues should be pursued. Ideally, data on patients with identical underlying causes of neurobehavioral abnormalities should be used to compare behavioral phenotype severity and variability with large genetic datasets in a personalized manner. Longitudinal research by monitoring tissue-specific mosaicism during the ontogeny along with evaluating general health and behavioral condition is likely to provide speculations on the associations between somatic mosaicism and behavioral variability. Finally, if this hypothesis is supported, somatic mosaicism will be referred to as a new connecting (or missing) link between genome, environment and behavior.
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